FMO5 and metabolic syndrome: Similarly, Mercer et al. (21) showed that MitoQ could decrease features (increased adiposity, hypercholesterolemia, and hypertriglyceridemia) of metabolic syndrome in a mouse model, while Feillet-Coudray et al. noted its superiority for xanthine oxidase and NADPH oxidase-dependent ROS production in mitigating metabolic syndrome features in an obesogenic diet-fed rat model (22).